Trials / Unknown
UnknownNCT02941679
Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients
A 24-week, Randomized, Double-Blind, Active-controlled, Parallel Study of HCP1202 Combination Product, HGP1011, and HCP0910 in Treatment of Subjects With COPD
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 252 (estimated)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A phase 3 study to evaluate efficacy and safety of HCP1202
Detailed description
This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of HCP1202 compared to either treatment with HGP1011 or HCP0910 in COPD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1202 | Hanmi Pharmaceutical. Co., Ltd. |
| DRUG | HGP1011 | Boehringer Ingelheim |
| DRUG | HCP0910 | GlaxoSmithKline |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-02-01
- Completion
- 2018-04-01
- First posted
- 2016-10-21
- Last updated
- 2016-10-21
Source: ClinicalTrials.gov record NCT02941679. Inclusion in this directory is not an endorsement.